TT5
Postoperative Pain
Phase 1Active
Key Facts
About Tafalgie Therapeutics
Tafalgie Therapeutics is a French biotech developing first-in-class, non-opioid analgesics targeting a significant unmet need in pain management. Its platform leverages the TAFA4 protein, discovered by co-founder Dr. Aziz Moqrich, which modulates pain signals between the peripheral and central nervous systems. The company has advanced its lead candidate, TT5, into Phase 1 clinical trials (TAFAFIRST study) and has demonstrated preclinical efficacy equivalent to morphine without associated adverse effects. As a private, pre-revenue entity, Tafalgie aims to become a leader in pain therapeutics through internal development and strategic partnerships.
View full company profileOther Postoperative Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| Alevatrix™ | Rebel Medicine | IND-enabling |
| SBG004 | Sonoran Biosciences | Pre-clinical/Phase 1 |
| LT1001 | Lumosa Therapeutics | Market |